3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
36
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
11
Neoplasms
9
Neoplasm Metastasis
9
Sarcoma
4
Lung Neoplasms
4
Esophageal Neoplasms
4
Adenocarcinoma
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Melanoma
3
Breast Neoplasms, Male
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Pancreatic Diseases
2
Metastatic Pancreatic Adenocarcinoma
2
Carcinoma
2
Advanced Solid Tumor
2
Tongue Neoplasms
1
Thymus Neoplasms
1
Solid Cancer
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Anal Cancer Metastatic
×
Albumin-Bound Paclitaxel
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled